Despite of the fact that further studies are needed to evaluate the efficacy of these selective class I HDACIs in other models of hepatic fibrogenesis, these evidences underscore the potential of class I HDAC inhibition as a therapy for liver fibrosis. This evidence concerns the gene HDAC9 and Hepatic fibrosis.